Drug Profile


Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Proteolix
  • Developer Dana-Farber Cancer Institute; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Mantle-cell lymphoma; Prostate cancer; Renal cell carcinoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute lymphoblastic leukaemia; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
  • Phase I Leukaemia; Lymphoid leukaemia
  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 18 May 2017 Ono Pharmaceuticals receives supplemental marketing and manufacturing approval for additional dosage and administration of carfilzomib with dexamethasone in Multiple myeloma in Japan
  • 26 Apr 2017 Onyx Therapeutics re-initiates enrolment in a phase Ib trial for Multiple myeloma (Combination therapy, Newly diagnosed, Second-line therapy) in USA (NCT02335983)
  • 24 Apr 2017 University Hospital Tuebingen plans a phase II trial for Multiple myeloma (Combination therapy, First-line therapy) in Germany (NCT03104842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top